Article Text

PDF

FRI0005 Safety of new cox-2 inhibitors in nsaid-intolerant patients
  1. M Sánchez-Borges,
  2. A Capriles-Hulett,
  3. F Caballero,
  4. C Pérez
  1. Allergy-Immunology, Clínica “El Avila”, Caracas, Venezuela

Abstract

Background Non-steroidal anti-inflammatory drug (NSAID)-triggered urticaria and angioedema occurrs in up to 3% of the population. The tolerance to new COX-2 selective inhibitors in intolerant patients has not been determined.

Objectives To study the clinical tolerance to Rofecoxib and Celecoxib in patients sensitive to conventional NSAIDs who develop urticaria and/or angioedema when exposed to these drugs.

Methods Sixty three subjects (female 44, male 19, mean age 33.0 ± 16.7 years, range 11 – 74 years) with challenge-proved urticaria/angioedema were studied. These patients were challenged by means of the single-blinded oral method, controlled with placebo.

Results Positive challenges were observed in 4 out of 53 subjects challenged with Rofecoxib (7.5%) and in 13 out of 47 individuals submitted to oral provocation with Celecoxib (27.6%) (p = 0.01).

Conclusion We conclude that: 1) The clinical tolerance to selective COX-2 inhibitors in NSAID-sensitive patients with skin manifestations differs between new drugs, which may be due to different degrees of enzyme selectivity or to other, not yet determined reasons.2) COX-1 inhibition would be involved in the production of cutaneous adverse reactions to NSAIDs.3) Controlled oral challenges are indicated especially for the management of sensitive individuals with chronic inflammatory and/or painful diseases.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.